“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s120. doi:10.25251/skin.7.supp.120.